Applied DNA Sciences Inc (APDN) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Applied DNA Sciences Inc (APDN) has a cash flow conversion efficiency ratio of -0.403x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-2.82 Million) by net assets ($6.99 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Applied DNA Sciences Inc market cap and net worth for the company's overall valuation and market capitalisation.
Applied DNA Sciences Inc - Cash Flow Conversion Efficiency Trend (2001–2025)
This chart illustrates how Applied DNA Sciences Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View current stock price of Applied DNA Sciences Inc for real-time trading data and today's change.
Applied DNA Sciences Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Applied DNA Sciences Inc ranked by their cash flow conversion efficiency. Review Applied DNA Sciences Inc free cash flow generation to assess how much free cash flow the company generates relative to operating cash flow.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Planet Properindo Jaya Pt
JK:PLAN
|
-0.004x |
|
Locafy Ltd
NASDAQ:LCFY
|
-0.083x |
|
International Biotechnology Trust plc
LSE:IBT
|
0.126x |
|
Clear Blue Technologies International Inc
V:CBLU
|
0.094x |
|
Prima Alloy Steel Universal
JK:PRAS
|
0.006x |
|
SILVER HAMMER MINING CORP
F:7BW0
|
-0.026x |
|
AM Resources Corp
V:AMR
|
-3.051x |
|
Digitalist Group Oyj
HE:DIGIGR
|
0.017x |
Annual Cash Flow Conversion Efficiency for Applied DNA Sciences Inc (2001–2025)
The table below shows the annual cash flow conversion efficiency of Applied DNA Sciences Inc from 2001 to 2025. Also see APDN asset base for a full breakdown of the balance sheet.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-09-30 | $1.94 Million | $-12.24 Million | -6.305x | -312.39% |
| 2024-09-30 | $8.97 Million | $-13.71 Million | -1.529x | -19.81% |
| 2023-09-30 | $4.87 Million | $-6.22 Million | -1.276x | -83.51% |
| 2022-09-30 | $12.91 Million | $-8.98 Million | -0.695x | +42.28% |
| 2021-09-30 | $11.11 Million | $-13.39 Million | -1.205x | +38.27% |
| 2020-09-30 | $5.71 Million | $-11.14 Million | -1.952x | -124.13% |
| 2019-09-30 | $-848.50K | $-6.86 Million | 8.087x | +188.21% |
| 2018-09-30 | $754.50K | $-6.92 Million | -9.168x | -740.66% |
| 2017-09-30 | $6.86 Million | $-7.48 Million | -1.091x | -14.22% |
| 2016-09-30 | $10.37 Million | $-9.90 Million | -0.955x | -72.25% |
| 2015-09-30 | $12.57 Million | $-6.97 Million | -0.554x | -109.56% |
| 2014-09-30 | $-1.47 Million | $-8.51 Million | 5.797x | +440.00% |
| 2013-09-30 | $4.62 Million | $-7.87 Million | -1.705x | +67.42% |
| 2012-09-30 | $756.92K | $-3.96 Million | -5.233x | -238.46% |
| 2011-09-30 | $-995.38K | $-3.76 Million | 3.779x | +145.98% |
| 2010-09-30 | $-1.60 Million | $-2.46 Million | 1.536x | +8.72% |
| 2009-09-30 | $-1.75 Million | $-2.47 Million | 1.413x | +577.91% |
| 2008-09-30 | $-14.04 Million | $-2.93 Million | 0.208x | +10.59% |
| 2007-09-30 | $-11.94 Million | $-2.25 Million | 0.189x | -37.34% |
| 2006-09-30 | $-9.59 Million | $-2.88 Million | 0.301x | +121.74% |
| 2005-09-30 | $6.59 Million | $-9.12 Million | -1.384x | -312.27% |
| 2004-09-30 | $-4.71 Million | $-3.07 Million | 0.652x | -23.40% |
| 2003-09-30 | $-577.43K | $-491.51K | 0.851x | -92.86% |
| 2001-09-30 | $-828.00 | $-9.87K | 11.914x | -- |
About Applied DNA Sciences Inc
Applied DNA Sciences, Inc., a biotechnology company, develops and commercializes technologies to produce and detect deoxyribonucleic acid (DNA) in the Americas, Europe, Asia, and internationally. It operates through three segments: Therapeutic DNA Production Services; MDx Testing Services; and DNA Tagging and Security Products and Services. The Therapeutic DNA Production Services segment develops… Read more